Biodistribution results showed that intraperineal administration was more effective than intravenous injection. The maximum tumor uptake with intraperitoneal administration was over 60 percent injected dose per gram (%ID/g) compared to about 18%ID/g with intravenous injection. A single dose of At211- trastuzumab (1 MBq) was sufficient to completely eradicate GC xenografts in two of six treated mice by inducing DNA double strand breaks, and reduce the tumor burden of three other mice.
No significant side effects such as weight loss, leucocytopenia, or damage to liver or kidney function were observed.
These results offer promise for At21-trastuzumab as a treatment option for HER2+ PMGC.
Presented By: Huizi Keiko Li from Graduate School of Medical and Pharmaceutical Sciences, Chiba University, Japan and Radiation and Cancer Biology Team, NIRS, QST, Japan
Written By: William Carithers, Lawrence Berkeley National Laboratory
at the 10th International Symposium on Targeted Alpha Therapy (TAT-10) May 31 - June 1, 2017 - Kanazawa, Japan.